Bruce McCall
Genentech
21 Papers
94 Citations
Bruce McCall is an academic researcher from Genentech. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 20 publications.
Chat about Author
Papers
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jérôme Fayette,Lori J. Wirth,Cristina Oprean,Anghel Udrea,Antonio Jimeno,Danny Rischin,Christopher M. Nutting,Paul M. Harari,Tibor Csoszi,Dana Cernea,Paul H. O'Brien,William D. Hanley,Amy V. Kapp,Maria Anderson,Elicia Penuel,Bruce McCall,Andrea Pirzkall,Jan B. Vermorken +17 more
TL;DR: The data indicate that inhibition of EGFR alone is sufficient to block EGFR–HER3 signaling, suggesting that HER2 plays a minimal role in this disease.
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Lihua E. Budde,Laurie H. Sehn,Sarit Assouline,Ian W. Flinn,Iris Isufi,Sung-Soo Yoon,Won Seog Kim,Matthew J. Matasar,Loretta J. Nastoupil,Raoul Santiago,Youngil Koh,Genevive Hernandez,Chi-Chung Li,Priya Kulkarni,Bruce McCall,Scott McClellan,Shen Yin,Vinita Gupta,Yu-Waye Chu,Nancy L. Bartlett +19 more
TL;DR: Primary outcome measures are maximum tolerated dose (MTD) based on dose-limiting toxicities (DLTs), tolerability, pharmacokinetics (PK), and best objective response (PK).
60
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
Andrew G. Hill,Michael Findlay,Matthew Burge,Christopher Jackson,Pilar García Alfonso,Leslie Samuel,Vinod Ganju,M. Karthaus,Alessio Amatu,Mark Jeffery,Maria Di Bartolomeo,John Bridgewater,Andrew L. Coveler,Manuel Hidalgo,Amy V. Kapp,Roxana Ioana Sufan,Bruce McCall,William D. Hanley,Elicia Penuel,Andrea Pirzkall,Josep Tabernero +20 more
TL;DR: Duligotuzumab plus F OLFIRI did not appear to improve the outcomes in patients with RAS exon 2/3 wild-type mCRC compared with cetuximab + FOLFIRI, and there was a trend for a lower objective response rate (ORR) in the duligosumab arm.
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno,Jean-Pascal Machiels,Lori J. Wirth,Pol Specenier,Tanguy Y. Seiwert,Feby Mardjuadi,X. Wang,Amy V. Kapp,Stephanie Royer-Joo,Elicia Penuel,Bruce McCall,Andrea Pirzkall,Paul Clement +12 more
TL;DR: This open‐label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual‐action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epiderm growth factor receptors (EGFR) in the first‐line treatment of patients with recurrent/metastatic squamous cell cancer of the head and neck.
41
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.
Josep Tabernero,John D. Powderly,Omid Hamid,Michael S. Gordon,George A. Fisher,Fadi Braiteh,Lawrence E. Garbo,Gregg Fine,Marcin Kowanetz,Bruce McCall,Xiaodong Shen,Daniel S. Chen,Holbrook E Kohrt +12 more
TL;DR: MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain designed to optimize efficacy and safety, targets PD-L1, blocking PD- L1 from binding its receptors, including PD-1 and B7, in patients with a broad range of tumors.
40